

**IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA**

**IN RE: GENERIC
PHARMACEUTICALS PRICING
ANTITRUST LITIGATION**

THIS DOCUMENT RELATES TO:

ALL END-PAYER ACTIONS

**MDL 2724
16-MD-2724
HON. CYNTHIA M. Rufe**

**CIVIL ACTION NO.
19-CV-06011-CMR**

**END-PAYER PLAINTIFFS' MOTION FOR LEAVE TO AMEND
THEIR SEPTEMBER 4, 2020 MULTI-DRUG COMPLAINT**

Pursuant to Federal Rule of Civil Procedure 15(a)(2), End-Payer Plaintiffs (“EPPs”) respectfully seek leave to amend their first amended complaint that was filed on September 4, 2020 in MDL 2724.

The proposed amendment seeks to correct and expand certain allegations in the existing complaint in response to new information obtained by EPPs.

The factual and legal bases for the motion are set forth in the attached End-Payer Plaintiffs’ Memorandum of Law in Support of Their Motion for Leave to Amend.

EPPs conferred with Defendants and they have not consented to the motion.

WHEREFORE, End Payer Plaintiffs respectfully request the Court grant this motion.

DATED: December 15, 2020

Respectfully submitted,

/s/ Roberta D. Liebenberg
Roberta D. Liebenberg
Fine, Kaplan and Black, R.P.C.
One South Broad Street, 23rd Floor
Philadelphia, PA 19107
(215) 567-6565

Lead Counsel for End-Payer Plaintiffs